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Autologous bone marrow mononuclear cell (BMMC) transplantation has emerged as a potential therapeutic
option for refractory angina patients. Previous studies have shown conflicting myocardium reperfusion re-
sults. The present study evaluated safety and efficacy of CellPraxis Refractory Angina Cell Therapy Protocol
(ReACT), in which a specific BMMC formulation was administered as the sole therapy for these patients.
The phase I/IIa noncontrolled, open label, clinical trial, involved eight patients with refractory angina and
viable ischemic myocardium, without left ventricular dysfunction and who were not suitable for conventional
myocardial revascularization. ReACT is a surgical procedure involving a single series of multiple injections
(40–90 injections, 0.2 ml each) into ischemic areas of the left ventricle. Primary endpoints were Canadian
Cardiovascular Society Angina Classification (CCSAC) improvement at 18 months follow-up and myocar-
dium ischemic area reduction (assessed by scintigraphic analysis) at 12 months follow-up, in correlation
with a specific BMMC formulation. Almost all patients presented progressive improvement in angina classi-
fication beginning 3 months (p = 0.008) postprocedure, which was sustained at 18 months follow-up (p =
0.004), as well as objective myocardium ischemic area reduction at 12 months (decrease of 84.4%, p <
0.004). A positive correlation was found between monocyte concentration and CCSAC improvement (r =
−0.759, p < 0.05). Improvement in CCSAC, followed by correlated reduction in scintigraphic myocardium
ischemic area, strongly suggests neoangiogenesis as the main stem cell action mechanism. The significant
correlation between number of monocytes and improvement strongly supports a cell-related effect of Re-
ACT. ReACT appeared safe and effective.
Key words: Monocytes; Angina; Cell therapy; Bone marrow mononuclear cell transplantation; Myocardia;
Ischemia
INTRODUCTION ten results in a substantial decrease in quality of life.
Symptom relief for the “no option” refractory angina
patient is a complex and challenging process. Alterna-Approximately 5–15% patients with chronic coro-
nary artery disease present severe disabling angina pec- tive therapies in compliance with the American Heart
Association Guidelines, such as surgical laser transmyo-toris that cannot be controlled by a combination of con-
ventional therapy tools, including multiple series of drug cardial revascularization, external counterpulsation, and
spinal cord stimulation, have all provided modest resultstherapy optimization treatments, percutaneous translu-
minal coronary angioplasty (PTCA), and coronary artery at best (13,16). The vast majority of refractory angina
pectoris patients (75%) have preserved left ventricularbypass grafting (CABG) (21). Severe angina pectoris of-
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function, with a mortality rate lower than the general Observing the minimal left ventricular improvement
and the clinical response of previous refractory anginacoronary heart disease population (22), and this patient
group is rapidly growing. trials, it is suggested that the primary action of bone
marrow stem cell transplantation in humans is promot-Cellular therapy, specifically autologous bone mar-
row cell transplantation, has emerged as a new therapeu- ing myocardial angiogenesis, and not pure myogenesis.
In this setting, angiogenesis can surely improve left ven-tic option for cardiac regeneration in both animal models
(14,17,42) and human studies (23,26,29,34,37,41). Some tricular function through rescuing or recruiting hibernat-
ing myocardium, but to a limited extent, as demon-hypothetical mechanistic explanations involve the stem
cells’ myogenic and angiogenic potential, and the acti- strated by these trials and some meta-analysis (1,18).
Previous preclinical and clinical studies have sup-vation of resident progenitor cell growth via paracrine
effects (2,9,36). ported the feasibility, safety, and efficacious potential of
stem cell therapy for myocardium tissue regenerationAlthough regeneration of myocardial tissue and con-
comitant reduction of the infarcted area have been dem- and encompasses patients presenting with a range of di-
agnoses from acute myocardial infarction to chronic is-onstrated in experimental animal models, many uncer-
tainties regarding the translation of these results into chemic heart disease (6,23,34,37,41).
The greatest challenge here consists in translatinghumans remain (33), rendering BMMC transplantation
for cardiac tissue regeneration an experimental proce- laboratory results to a standard clinical procedure. Dif-
ferences in study design, stem and mononuclear celldure, not a standard of care for clinical practice.
Nevertheless, refractory angina patients may benefit preparation, and infusion techniques have delivered
somewhat promising, but overall inconsistent, data fromfrom cellular-based therapy, particularly in regards to
angiogenesis. These angiogenic effects are considered different studies (31).
The aim of our study was to evaluate the safety andamong investigators to be very important when cell ther-
apy is considered an option for human patients (19). efficacy of a proprietarily designed protocol, the Cell-
Praxis Refractory Angina Cell Therapy Protocol (Re-Angiogenic effects were reported in several preclini-
cal studies (6,19). Mobilization of mouse bone marrow ACT), in which a single series of multiple intramyocar-
dial injections of a specific BMMC formulation is(BM) cells (25) or sheep cord blood mononuclear cells
(42) into the circulation after acute myocardial infarction performed as the sole surgical therapy for these patients.
ReACT was designed in compliance with Good Man-resulted in regeneration of myocytes and vascular struc-
tures. This functional benefit in BM cell implantation is ufacturing Practices (GMP) and FDA standards criteria.
Inclusion criteria for this study required patients diag-likely attributed to a paracrine effect with an increase in
angiogenesis through local release of multiple growth nosed with refractory angina pectoris, with viable myo-
cardium (diagnosed through stress tecnecium scintigra-factors, such as vascular endothelial growth factor and
stromal cell-derived factor-1, among others (19). phy), without left ventricular dysfunction (ejection fraction
of at least 45%) and who were not suitable for myocar-In clinical studies involving refractory angina pa-
tients, who received bone marrow-derived stem cells or dial revascularization (either PTCA or CABG).
Eight refractory angina patients were included in theBMMC, improvement in symptoms and exercise capac-
ity, as well as in myocardial perfusion were observed study from September 2005 to July 2007. All patients
had previously undergone surgical revascularization [once(4,5,19,27,35). Beeres et al. (3) conducted a trial using
intramyocardial injection of autologous BMMC in 25 (four patients), twice (three patients), or four (one pa-
tient) times] without angina relief. Patients’ baselinepatients with refractory angina, which showed sustained
beneficial effects on anginal symptoms and myocardial characteristics are described on Table 1.
An additional four refractory angina patients were en-perfusion. Losordo et al. (20) performed a phase I/IIa,
double-blind, randomized, placebo-controlled dose-esca- rolled and underwent ReACT, but required simultaneous
coronary artery bypass grafting and were excluded fromlating clinical trial with endomyocardial injection of au-
tologous CD34+ stem cells for refractory angina patients, this analysis. These patients are currently being followed
as a separate group.demonstrating a trend of increased exercise time, in ad-
dition to Canadian Cardiovascular Society Angina Clas-
sification (CCSAC) improvement among CD34+ cell- MATERIALS AND METHODS
treated patients. van Ramshorst et al. (38) conducted a Study Design/Study Population
randomized controlled trial of intramyocardial bone
marrow cell injection for refractory angina, with a short- The study was a phase I/IIa noncontrolled open label
clinical trial. Refractory angina patients routinely under-term follow-up (3–6 months) showing a modest im-
provement in myocardial perfusion compared with pla- going treatment at the Sa˜o Paulo Hospital, in Sa˜o Paulo,
Brazil, a referral tertiary Federal University Hospital forcebo.
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coronary heart disease, were included in the study. The formulation injections into the left ventricular myocar-
dium were performed surgically, through a left lateralstudy protocol (ReACT) was approved by our local and
national ethical committee (CEP-EPM-0314/05), and all thoracotomy, as follows: 0.2 ml (2 × 106 cells)/injection,
1 cm distance between injections, and 1 cm epimyocar-patients provided written informed consent. Refractory
angina patients were defined as those with functional dial depth infusion. The number of injections (40–90)
for each patient differed based on the extension of myo-class IV (angina at rest) according to the CCSAC despite
maximum medical therapy, not suitable for conventional cardium viable ischemic area determined on nuclear im-
aging tests, and left ventricular chamber size.myocardial revascularization and with viable myocar-
dium identification. Ineligibility for revascularization—
Follow-upeither percutaneous or surgical—was determined by at
least two cardiologists and two cardiovascular surgeons Patients’ heart rhythm was monitored for 48 h after
based on the most recent (within 6 months) patient’s surgery. Clinical evaluation of CCSAC was carried out
coronary angiogram. Exclusion criteria were: (a) left at months 3, 6, 12, and 18 after surgery. Echocardiogram
ventricular ejection fraction (LVEF) <45% on transtho- was performed at baseline (prior to patient inclusion)
racic echocardiogram; (b) absence of viable myocar- and 1, 3, 6, and 12 months and magnetic resonance
dium on cardiac nuclear imaging test; (c) positive sero- (MR) of the heart at baseline and months 6 and 12 to
logic tests for human immunodeficiency virus (HIV), assess safety. Nuclear imaging test (tecnecium stress-in-
types A, B, and C hepatitis, human T-cell lymphotropic duced myocardium perfusion scintigraphy) was per-
virus (HTLV), or Chagas disease; (d) significant heart formed at baseline and 6 and 12 months after the proce-
valve disease; (e) chronic renal disease in dialysis; (f) dure to evaluate the percentage of myocardium ischemic
abusive use of alcohol and drugs; (g) any other medical area. It is important to point out, regarding ischemic
condition with estimated survival <5 years; (h) participa- heart area objective analysis (stress scintigraphy), that
tion in prior cell therapy studies; and (i) pregnancy. all patients were considered to have 100% of viable
myocardium ischemic area on those specific left ventric-
Study Procedures ular walls identified by stress tecnecium scintigraphy,
prior to cell formulation injection. These reversible is-For each patient, a total of 100 cc of bone marrow
chemic heart areas were considered baseline comparisonwas aspirated from the iliac crest, and stored in a saline
to 6 and 12 months scintigraphic analysis follow-up.solution of 80 IU heparin/ml. Mononuclear cells were
Scintigraphic analysis was only performed at 6 and 12isolated by density gradient, and diluted to a final con-
months follow-up.centration of 107 cells/ml, in accordance with ReACT
and GMP. Cell viability, total mononuclear, leukocyte
Statistical Analysisdifferential counting (including monocytes concentra-
tion), and CD34+ content, as well as aerobe and anaer- The Friedman nonparametric test was used to assess
changes from baseline in angina CCSAC class at 3, 6,obe microbiology tests, were performed. Samples for fu-
ture evaluation were stored. One series of multiple cell and 12 months and in myocardium ischemic area at 6
Table 1. Patients’ Baseline Characteristics
Drug
Therapy Ejection Previous
Patient Age Gender Diabetes Optimization Fraction CABG (n) CCSAC
1 62 male yes yes 63% yes (1) 4
2 70 male no yes 63% yes (2) 4
3 58 male no yes 74% yes (2) 4
4 72 female yes yes 59% yes (2) 4
5 75 male yes yes 56% yes (1) 4
6 79 male yes yes 61% yes (1) 4
7 53 male no yes 47% yes (4) 4
8 53 female yes yes 62% yes (1) 4
Drug therapy optimization is defined as repeated attempts of drug therapy optimization and combina-
tion, including maximum dosage of beta blockers, angiotensin converting enzyme inhibitors, calcium
channel blockers, short- and long-lasting action nitrates, statins, and antiplatelets, for at least 3
months prior to patient meeting inclusion criteria.
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and 12 months of follow-up. For post hoc comparisons,
the Wilcoxon test with Bonferroni’s correction was
used. Correlation between outcomes (angina class and
myocardium ischemic area after the procedure) and the
injections number was assessed by Spearman test. To
compare the left ventricular function on echocardiogram
before and at 12 months after the procedure, the Wilco-
xon nonparametric test was used.
RESULTS
Subjective Improvement in Myocardial Ischemia
After the ReACT myocardial injection procedure,
there was a progressive improvement in the angina clas-
sification median, varying from class 4 at baseline to 2.3
(p = 0.008), 1.5 (p = 0.008), 0.9 (p = 0.004), and 0.9 (p =
0.004) at 3, 6, 12, and 18 months of follow-up, respec-
tively (Fig. 1, Table 2).
Objective Improvement in Myocardial Ischemia
A progressive reduction in ischemic myocardium
area was observed by stress tecnecium scintigraphy after
Figure 1. Variations in CCSAC over 18 months follow-up. 6 months (decrease of 39.4%, p = 0.06) and 12 monthsEach line in the graphic represents one patient enrolled in Re- (decrease of 84.4%, p < 0.004), although the differenceACT and the corresponding CCSAC improvement over the
was statistically significant only at 12 months. It is im-18-month follow-up. The x-axis represents CCSAC class
(number 4 for refractory angina pectoris, and number 0 for no portant to note that all patients were considered to have
pain). The y-axis represents patient follow-up in months. One- 100% of viable myocardium ischemic area on those spe-
tailed Wilcoxon test statistical analysis of CCSAC improve-
cific left ventricular walls identified by stress tecnecium
ment was significant at 3 (0.008), 6 (0.008), 12 (0.004), and
scintigraphy, prior to cell formulation injection. These18 (0.004) months follow-up compared to baseline; variation
initial reversible ischemic heart areas were consideredin angina class is statistically significant if p < 0.0125 (0.05/4)
(Bonferroni’s correction). baseline when compared to 6 and 12 months scinti-
graphic analysis follow-up (Fig. 2, Fig. 3, Table 2).
Table 2. Variation in Angina Classification and Myocardium Ischemic Area After the ReACT Infusion
Canadian Cardiovascular Society Angina Classification (p < 0.001) % Ischemic Area* (p < 0.002)
6 Months 12 Months 18 Months 6 Months 12 Months
Patient Pre 3 Months of Follow-up of Follow-up of Follow-up Pre† of Follow-up of Follow-up
1 4 2 2 1 1 100 0 0
2 4 1 0 0 0 100 0 0
3 4 3 2 1 1 100 0 0
4 4 3 2 1 1 100 100 0
5 4 1 0 0 0 100 100 40
6 4 3 2 1 1 100 100 0
7 4 4 4 3 3 100 85 85
8 4 1 0 0 0 100 100 0
Mean 4 2.3 1.5 0.9 0.9 100 60.6 15.6
Median 4 2.5 2.0 1.0 1.0 100 92.5 0.0
p-Value (unilateral
Wilcoxon test)‡ 0.008 0.008 0.004 0.004 0.063 0.004
*Assessed by stress tecnecium scintigraphy.
†All patients were considered to have 100% of viable myocardium ischemic area on those specific left ventricular walls identified by stress
tecnecium scintigraphy, prior to cell formulation injection. The 6- and 12-month analysis reflects the myocardium ischemic area percentage reduction
on these walls.
‡Related to baseline; variation in angina class and ischemic myocardium area statistically significant if p < 0.0125 (0.05/4) and p < 0.025 (0.05/2)
(Bonferroni’s correction), respectively.
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correlation was found between the number of punctures
(the “act of introducing the needle” into the heart mus-
cle) and angina classification improvement at 3, 6, 12,
and 18 months. Also, there was no correlation between
the number of punctures and changes in ischemic myo-
cardium area at 6 and 12 months of follow-up, as shown
in Table 5 and Figures 5 and 6.
Left Ventricular Ejection Fraction
The difference in LVEF median assessed by echocar-
diogram was not statistically significant, according to
Wilcoxon test, varying from 60.6 ± 7.6% at baseline to
61.1 ± 6.5% at 12 months follow-up (p = 0.726) (see
Fig. 7).
Safety
None of the patients presented arrhythmia, or local
(as assessed by heart magnetic resonance imaging) or
systemic neoplasia up to 18 months after the procedure.
DISCUSSION
The results of this study demonstrate that ReACT
may benefit refractory angina patients, who are not suit-
Figure 2. Variations in myocardial ischemic area evaluated by able for conventional myocardial revascularization, and
stress tecnecium scintigraphy at 12 months follow-up. Each show signs of angina at rest despite maximum medical
line in the graphic represents one patient enrolled in ReACT therapy. Our findings demonstrate an improvement in
and the corresponding scintigraphic myocardium ischemic
angina symptoms and a decrease in the extent of myo-area improvement over 12 months follow-up. The x-axis repre-
cardial ischemia. The probable causal mechanism of thissents the percentage of scintigraphic myocardial ischemic area.
The y-axis represents patient follow-up in months (scinti- improvement may be angiogenic properties of ReACT
graphic analysis was assessed only at 6 and 12 months). One- formulation.
tailed Wilcoxon test statistical analysis of scintigraphic myo- In our study, angina symptom relief began as early as
cardium ischemic area improvement was not significant at 6 3 months postprocedure with continuing improvement(0.063) but was significant at 12 (0.004) months follow-up
through 12 months and sustained improvement throughcompared to baseline; variation in scintigraphic myocardium
ischemic area improvement is statistically significant if p < 18 months, suggesting that angiogenesis began early,
0.025 (0.05/2) (Bonferroni’s correction). and that it kept evolving 18 months after the procedure
(see Table 2 and Fig. 1). Furthermore, symptom relief
progressively improved in all patients, suggesting that
Correlation Between ReACT’s Formulation the effect is sustained and not transitory, a result differ-
and Improvement ent from other studies (5). Accordingly, the myocardial
ischemia area percentage showed a decreasing trend, ul-ReACT has a certain percentage of monocytes (12.4
± 3.5; range 8.0–18.4) (see Table 1 for more details) and timately reaching significance at 12 months. The fact
that symptom improvement occurred much earlier thanits specific formulation positively correlates with clini-
cal response: specifically, improvement in CCSAC (Ta- perfusion improvement might be explained by nuclear
imaging testing’s low spatial resolution and high vari-ble 4, Fig. 4).
Other cell types such as lymphocytes or CD34+ cells ability, preventing it from detecting small changes, espe-
cially in such a small patient population.showed no correlation with CCSAC or myocardium is-
chemic area improvement. The natural history of refractory angina shows that
spontaneous remissions of even severe angina may oc-
Correlation Between Number of Myocardium cur (16,22,30). Looking at medically treated groups of
Punctures and Improvement randomized studies at 12 months posttreatment, up to
19% of patients included in percutaneous myocardial la-The number of myocardium punctures varied from
40 to 90 in each patient (58 ± 14.9), depending on the ser revascularization trials and up to 32% of patients
(and up to 44% at 36 months) for surgical myocardialextent of the left ventricular ischemic area, as deter-
mined by stress tecnecium scintigraphy. No significant laser revascularization studies had an improvement of at
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Figure 3. Comparison between the scintigraphic myocardium stress perfusion area from baseline
to 6 and 12 months after ReACT procedure, in two patients. (A) Refractory angina, at baseline.
(B) Reduction of myocardium ischemic area. (C) Absence of myocardium ischemic area.
least two points in CCSAC (24). Our results show a with viable myocardium and preserved left ventricular
function would be the ideal candidate for an angiogenicmuch compelling and greater CCSAC improvement, re-
inforced by the tangible myocardium perfusion stress therapy employing ReACT intramyocardial injection.
For obvious reasons, analysis of LVEF is not an end-testing.
Refractory angina studies include mainly patients point for this group. The primary therapeutic goal is
myocardial perfusion improvements using ReACT for-with moderate to severe left ventricular dysfunction. As
a result, our study showed better improvement in angina mulation in a subjective (CCSAC) and objective (stress-
induced myocardium imaging testing) perspective.symptoms and quality of life, rather than benefits in left
ventricular ejection fraction (LVEF). In our study, all Different from other studies, ReACT has a specific
cell formulation, which seems to correlate with clinicalpatients had LVEF ≥ 45% at baseline and, as expected,
there was no significant change in LVEF at 12 months and scintigraphic responses: an improvement in angina
classification and a reduction in myocardium ischemic(p = 0.726). These findings also suggest angiogenesis
directly related to stem cell infusion and not myocardial area, respectively. Improvement in CCSAC (subjective
measure), followed by correlated reduction in myocar-punctures promoting secondary angiogenesis. On the
other hand, the sustained LVEF as well as the myocar- dium ischemic area (objective measure), strongly sug-
gests neoangiogenesis as the main stem cell actiondial perfusion improvement suggests absence of func-
tional deficit due to myocardium necrosis or fibrosis mechanism (Figs. 1 and 2). Consequently, the large frac-
tion of monocytes present in ReACT seems to be relatedpromoted by the intramyocardial ReACT injections, re-
inforcing the procedure safety. to the angiogenesis that restores the perfusion of the
myocardial ischemic areas after the cell transplantation.The standard refractory angina patient population
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Table 3. Percentage of Monocyte Concentration in ReACT endothelial-like cells. Furthermore, the endothelial cell
in Each Patient production of MCP-1, VEGF, and angiopoietin initiated
by VEGF exposure or hypoxia activate and attract more
Patient Monocyte Concentration
monocytes/macrophages, resulting in an auto feedback
of the angiogenic process (32).1 —
The optimal number or formulation of stem cells to2 18.36
3 11.20 promote myocardial regeneration remains controversial
4 13.92 among different investigators, most of them showing no
5 14.47 dose-dependent effect (7,8).
6 9.52 Henning et al. (10) injected human cord blood-
7 7.99 derived bone marrow stem cells in infarcted rats, com-
8 11.20 paring different doses and routes of administration
(intramyocardial, intracoronary, or intravenous), demon-Please note that monocyte data for patient number 1 are not available.
strating higher effectiveness with the intramyocardial in-
jection. In our study, we performed ReACT, a single
series of multiple injections with 2 × 106 BMMC formu-The mechanisms are not yet elucidated and will be ana-
lyzed in the next phase of this study. Nevertheless, a lation/myocardium puncture. There was no correlation
between the number of injections and the angina classi-significant correlation between number of monocytes
and improvement of clinical response (r = −0.759, p < fication variation over time; however, the study popula-
tion was probably too small for any significant associa-0.05) strongly supports a cell related effect of ReACT
in this study. tion to be reached and as the ReACT protocol is
designed to continue, future data may or may not con-This positive correlation between the number of
monocytes in ReACT and the sustained improvement firm this.
The intramyocardial route of cell formulation deliv-in angina class could indicate the importance of these
supporting cells for BMMC mechanism of action and ery was selected based upon experimental data that
shows higher myocardial stem cell uptake through intra-sustained myocardium angiogenesis. The importance of
monocytes in the transplantation of mononuclear cells myocardial infusion, in comparison to other routes, such
as intracoronary (either anterograde or retrograde injec-has also been shown in the treatment of stroke (39,40).
Also critical, these data support the hypothesis that the tion) or transcoronary (6,10,28). Also, the chronic clini-
cal feature of refractory angina provides a much saferresults of this study are due to a cellular effect of Re-
ACT formulation and not to nonspecific effects of the profile for an intramyocardial approach, without major
complication concerns, like intramyocardial injection inReACT procedure. Future controlled studies will further
clarify. the acute setting (acute myocardial infarction).
It is important to point out that, although promising,Bone marrow is a natural source of a broad spectrum
of cytokines that are involved in the control of angio- we understand our study has some limitations. While
our study included a larger number of patients with agenic and inflammatory processes. Bone marrow leuko-
cytes play an important role in the angiogenic mecha- significantly greater follow-up time than most published
refractory angina studies, the small sample size of eightnism, and neutrophils and monocytes act as a key in this
process (12,15). patients makes efficacy determination difficult, but has
been able to demonstrate safety. Due to ethical aspectsMonocytes/macrophages essentially contribute to neo-
vascularization in heart and other ischemic diseases, re- and the inability to justify the use of an isolated surgical
intramyocardial placebo in this population, this was agardless of the mechanism involved (either arteriogene-
sis or angiogenesis) (11,32). nonrandomized, open study; consequently, a placebo ef-
fect cannot be ruled out. However, it should be empha-When arteriogenesis is the main process, monocytes
can promote endothelial and smooth muscle cell prolif- sized that an objective increase in myocardium perfusion
was also assessed and maintained over time.eration, through a significant increase in monocyte che-
motactic protein-1 (MCP-1) (32). Other clinical studies still need to confirm our results.
However, the effectiveness of this ReACT procedure, inIn angiogenesis, VEGF and angiopoietin induce the
recruitment of endothelial progenitor cells and mono- compliance with the technical and GMP specifications
as well as a specific cell preparation of ReACT, seemcytes/macrophages. These recruited monocytes/macro-
phages promote angiogenesis by several potential mech- to deliver better outcomes than previously reported by
other investigators.anisms, including endothelial cell migration, proliferation
or tube formation, growth factors mobilization, proangi- In conclusion, surgical intramyocardial transplanta-
tion of an autologous, bone marrow-derived cell prepa-ogenic cytokines release, and transdifferentiation into
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Table 4. Spearman’s Correlation Coefficients (rs) Between ReACT Monocyte
Content, Lymphocytes, and CD34+ Cells and Improvement of Angina
Classification and Percent Myocardium Ischemic Area in the Follow-up
Monocytes Lymphocytes CD34+
Angina class: 3 months follow-up (n = 7)
rs −0.759 0.579 −0.318
p-Value 0.048 0.174 0.487
Angina class: 6 months follow-up (n = 7)
rs −0.759 0.579 −0.458
p-Value 0.048 0.174 0.301
Angina class: 12 months follow-up (n = 7)
rs −0.759 0.579 −0.458
p-Value 0.048 0.174 0.301
Angina class: 18 months follow-up n = 7)
rs −0.759 0.579 −0.458
p-Value 0.048 0.174 0.301
% Ischemic area: 6 months follow-up (n = 7)
rs −0.101 0.339 0.077
p-Value 0.830 0.457 0.869
% Ischemic area: 12 months follow-up (n = 7)
rs −0.270 0.267 −0.204
p-Value 0.559 0.562 0.661
For technical reasons, we do not have cell counting and percentage for the first patient enrolled in
the study; therefore, analysis is only seven patients. Angina class was assessed according to Cana-
dian Cardiovascular Society Angina Classification. Percent ischemic area improvement assessed
by stress tecnecium scintigraphy.
Figure 4. Correlation between monocyte concentration in ReACT and CCS improvement in 18 months follow-up. Each point
represents one patient. The x-axis corresponds to the monocyte concentration and the y-axis corresponds to number of CCS classes
improved.
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Table 5. Spearman’s Correlation Coefficients (rs) Between Number of Punctuations and Results
of CCSAC and Percent Myocardium Ischemic Area Improvement During Follow-up
Angina Angina Angina Angina % Ischemic % Ischemic
Class: Class: Class: Class: Area: Area:
3 Months 6 Months 12 Months 18 Months 6 Months 12 Months
Injections Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up
rs −0.403 −0.216 −0.216 −0.216 −0.203 −0.204
p-Value 0.322 0.607 0.607 0.607 0.629 0.628
Angina class assessed according to Canadian Cardiovascular Society Angina Classification. Percent ischemic
area improvement as assessed by stress tecnecium scintigraphy. N = 8 for all.
Figure 5. Correlation between number of myocardium punctures and CCS improvement in 18 months follow-up. Each point in the
graphic represents one patient. The x-axis corresponds to the number of myocardium punctures and the y-axis corresponds to
number of CCS classes improved.
Figure 6. Correlation between number of myocardium punctures and myocardium ischemic area reduction, as assessed by stress
scintigraphy. Each point in the graphic represents one patient. The x-axis corresponds to the number of myocardium punctures and
the y-axis corresponds to percentage of myocardium ischemic area improved.
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Figure 7. Comparison between left ventricular ejection fraction, as assessed by transthoracic echocardiogram, at baseline and 12
months follow-up. The left bar represents baseline left ventricular ejection fraction, while the right one represents the ejection
fraction at 12 months. The x-axis corresponds to echocardiographic left ventricular ejection fraction (in %) and the y-axis corre-
sponds to time point, in months (where 0 = baseline).
4. Beeres, S. L.; Bax, J. J.; Kaandorp, T. A.; Zeppenfeld, K.;ration, in a standardized protocol, may be a safe and
Lamb, H. J.; Dibbets-Schneider, P.; Stokkel, M. P.; Fibbe,effective procedure in promoting progressive and sus- W. E.; de Roos, A.; van der Wall, E. E.; Schalij, M. J.;
tained improvement in patients with refractory angina. Atsma, D. E. Usefulness of intramyocardial injecton of
autologous bone marrow-derived mononuclear cells in pa-ACKNOWLEDGMENTS: We wish to thank Dong-Hyuk Park,
tients with severe angina pectoris and stress-induced myo-David Eve, and Nicole Kuzmin-Nichols for revisions. We also
cardial ischemia. Am. J. Cardiol. 97:1326–1331; 2006.wish to thank Cryopraxis Crobiologia Ltda. and Cellpraxis
5. Briguori, C.; Reimers, B.; Sarais, C.; Napodano, M.;Biogenharia for grant support and funding. Dr. Amit Patel,
Pascotto, P.; Azzarello, G.; Bregni, M.; Porcellini, A.;Cardiovascular Systems Section Editor, handled all editorial
Vinante, O.; Zanco, P.; Peschle, C.; Condorelli, G.;peer review, determination of reviewers, and final acceptance
Colombo, A. Direct intramyocardial percutaneous deliv-of this article in a blinded fashion to all authors. N.A.H.,
ery of autologous bone marrow in patients with refractoryA.L.I., and P.R.S. are inventors on a patent application sub-
myocardial angina. Am. Heart J. 151:674–680; 2006.mitted in regards to the technology related to this article.
6. Charwat, S.; Gyo¨ngyo¨si, M.; Lang, I.; Graf, S.; Beran, G.;N.A.H. and P.R.S. are consultants for Cryopraxis. ReACTTM is
Hemetsberger, R.; Nyolczas, N.; Sochor, H.; Glogar, D.a trademark licensed to Cryopraxis.
Role of adult bone marrow stem cells in the repair of is-
chemic myocardium: Current state of the art. Exp. Hema-REFERENCES tol. 36:672–680; 2008.
7. Hale, S. L.; Dai, W.; Dow, J. S.; Kloner, R. A Mesenchy-1. Abdel-Latif, A.; Bolli, R.; Tleyjeh, I. M.; Montori, V. M.;
mal stem cell administration at coronary artery reperfusionPerin, E. C.; Hornung, C. A.; Zuba-Surma, E. K.; Al-
in the rat by two delivery routes: A quantitative assess-Mallah, M.; Dawn, B. Adult bone marrow-derived cells
ment. Life Sci. 83:511–515; 2008.for cardiac repair. A systematic review and meta-analysis.
8. Hashemi, S. M.; Ghods, S.; Kolodgie, F. D.; Parcham-Arch. Intern. Med. 167:989–997; 2007.
Azad, K.; Keane, M.; Hamamdzic, D.; Young, R.; Rippy,2. Anversa, P.; Leri, A.; Rota, M.; Hosoda, T.; Bearzi, C.;
M. K.; Virmani, R.; Litt, H.; Wilensky, R. L. A placeboUrbanek, K.; Kajstura, J.; Bolli, R. Concise review: Stem
controlled, dose-ranging, safety study of allogenic mesen-cells, myocardial regeneration, and methodological arti-
chymal stem cells injected by endomyocardial deliveryfacts. Stem Cells 25:589–601; 2007.
after an acute myocardial infarction. Eur. Heart J. 29:251–3. Beeres, S. L.; Bax, J. J.; Dibbets-Schneider, P.; Stokkel,
259; 2008.M. P.; Fibbe, W. E.; van der Wall, E. E.; Schalij, M. J.;
9. Henning, R. J.; Abu-Ali, H.; Balis, J. U.; Morgan, M. B.;Atsma, D. E. Sustained effect of autologous bone marrow
Willing, A. E.; Sanberg, P. R. Human Umbilical cordmononuclear cell injection in patients with refractory an-
blood mononuclear cells for the treatment of acute myo-gina pectoris and chronic myocardial ischemia: Twelve-
cardial infarction. Cell Transplant. 13:729–739; 2004.month follow-up results. Am. Heart J. 152:684.e11–16;
10. Henning, R. J.; Burgos, J. D.; Vasko, M.; Alvarado, F.;2006.
REFRACTORY ANGINA CELL THERAPY (ReACT): A ROLE FOR MONOCYTES 1309
Sanberg, C. D.; Sanberg, P. R.; Morgan, M. B. Human 21. Mannheimer, C.; Camici, P.; Chester, M. R.; Collins, A.;
DeJongste, M.; Eliasson, T.; Follath, F.; Hellemans, I.;cord blood cells and myocardial infarction: Effect of dose
and route of administration on infarct size. Cell Trans- Herlitz, J.; Lu¨scher, T.; Pasic, M.; Thelle, D. The problem
of chronic refractory angina. Report from de ESC jointplant. 16:907–917; 2007.
11. Hirose, N.; Maeda, H.; Yamamoto, M.; Hayashi, Y.; Lee, study group on the treatment of refractory angina. Eur.
Heart J. 23:355–370; 2002.G-H.; Chen, L.; Radhakrishnan, G.; Rao, P.; Sasaguri, S.
The local injection of peritoneal macrophages induces 22. Moore, R. K.; Groves, D.; Bateson, S.; Barlow, P.;
Hammond, C.; Leach, A. A.; Chester, M. R. Health re-neovascularization in rat ischaemic hind limb muscles.
Cell Transplant. 17:211–222; 2008. lated quality of life of patients with refractory angina be-
fore and one year after enrolment onto a refractory angina12. Hoefer, I. E.; Grundmann, S.; van Royen, N.; Voskuil, M.;
Schirmer, S. H.; Ulusans, S.; Bode, C.; Buschmann, I. R.; program. Eur. J. Pain 9:305–310; 2005.
23. Nasseri, B. A.; Kukucka, M.; Dandel, M.; Knosalla, C.;Piek, J. J. Leukocyte subpopulations and arteriogenesis:
Specific role of monocytes, lymphocytes and granulo- Potapov, E.; Lehmkuhl, H. B.; Meyer, R.; Ebell, W.;
Stamm, C.; Hetzer, R. Intramyocardial delivery of bonecytes. Atherosclerosis 181:285–293; 2005.
13. Jolicoeur, E. M.; Granger, C. B.; Henry, T. D.; Holmes, marrow mononuclear cells and mechanical assist device
implantation in patients with end-stage cardiomyopathy.D. J.; Pepine, C. J.; Mark, D.; Chaitman, B. R.; Gersh,
B. J.; Ohman, E. M.; Working Group Members. Clinical Cell Transplant. 16(9):941–949; 2007.
24. Nordrehaug, J. E.; Salem, M. Treatment of chronic refrac-and research issues regarding chronic advanced coronary
artery disease: Part I: Contemporary and emerging thera- tory angina pectoris—light at the end of the tunnel? Eur.
Heart J. 27:1007–1009; 2006.pies. Am. Heart J. 155:418–434; 2008.
14. Krausgrill, B.; Vantler, M.; Burst, V.; Raths, M.; Halbach, 25. Orlic, D.; Kajstura, J.; Chimenti, S.; Jakoniuk, I.; Ander-
son, S. M.; Li, B.; Pickel, J.; McKay, R.; Nadal-Ginard,M.; Frank, K.; Schynkowski, S.; Schenk, K.; Hescheler,
J.; Rosenkranz, S.; Mu¨ller-Ehmsen, J. Influence of cell B.; Bodine, D. M.; Leri, A.; Anversa, P. Bone marrow
cells regenerate infarcted myocardium. Nature 410:701–treatment with PDGF-BB and reperfusion on cardiac per-
sistence of mononuclear and mesenchymal bone marrow 705; 2001.
26. Patel, A. N.; Sherman, W. Cardiac stem cell therapy fromcells after transplantation into acute myocardial infarction
in rats. Cell Transplant. 18(8):847–853; 2009. bench to bedside. Cell Transplant. 16:875–878; 2007.
27. Perin, E. C.; Dohmann, H. F.; Borojevic, R.; Silva, S. A.;15. Kusumanto, Y. H.; Dam, W. A.; Hospers, G. A. P.;
Meijer, C.; Mulder, N. H. Platelets and granulocytes, in Sousa, A. L.; Mesquita, C. T.; Rossi, M. I.; Carvalho,
A. C.; Dutra, H. S.; Dohmann, H. J.; Silva, G. V.; Bele´m,particular the neutrophils, form important compartments
for circulating vascular endothelial growth factor. Angio- L.; Vivacqua, R.; Rangel, F. O.; Esporcatte, R.; Geng, Y. J.;
Vaughn, W. K.; Assad, J. A.; Mesquita, E. T.; Willerson,genesis 6:283–287; 2003.
16. Leon, M. B.; Kornowski, R.; Downey, W. E.; Weisz, G.; J. T. Transendocardial, autologous bone marrow cell
transplantation for severe, chronic ischemic heart failure.Baim, D. S.; Bonow, R. O.; Hendel, R. C.; Cohen, D. J.;
Gervino, E.; Laham, R.; Lembo, N. J.; Moses, J. W.; Circulation 107:2294–2302; 2003.
28. Perin, E. C.; Silva, G. V.; Assad, J. A.; Vela, D.; Buja,Kuntz, R. E. A blinded, randomized, placebo-controlled
trial of percutaneous laser myocardial revascularization to L. M.; Sousa, A. L.; Litovsky, S.; Lin, J.; Vaughn, W. K.;
Coulter, S.; Fernandes, M. R.; Willerson, J. T. Compari-improve angina symptoms in patients with severe coro-
nary disease. J. Am. Coll. Cardiol. 46:1812–1819; 2005. son of intracoronary and transendocardial delivery of allo-
geneic mesenchymal cells in a canine model of acute17. Li, T. S.; Mikamo, A.; Takahashi, M.; Suzuki, R.; Ueda,
K.; Ikeda, Y.; Matsuzaki, M.; Hamano, K. Comparison of myocardial infarction. J. Mol. Cell. Cardiol. 44:486–495;
2008.cell therapy and cytokine therapy for functional repair in
ischemic and nonischemic heart failure. Cell Transplant. 29. Ramos, G. A.; Hare, J. M. Cardiac cell-based therapy:
Cell types and mechanisms of actions. Cell Transplant.16(4):365–374; 2007.
18. Lipinski, M. J.; Biondi-Zoccai, G. G.; Abbate, A.; Khia- 16:951–961; 2007.
30. Rana, J. S.; Mannam, A.; Donnell-Fink, L.; Gervino, E. V.;ney, R.; Sheiban, I.; Bartunek, J.; Vanderheyden, M.; Kim,
H. S.; Kang, H. J.; Strauer, B. E.; Vetrovec, G. W. Impact Sellke, F. W.; Laham, R. J. Longevity of the placebo ef-
fect in the therapeutic angiogenesis and laser myocardialof intracoronary cell therapy on left ventricular function in
the setting of acute myocardial infarction: A collaborative revascularization trials in patients with coronary heart dis-
ease. Am. J. Cardiol. 95:1456–1459; 2005.systematic review and meta-analysis of controlled clinical
trials. J. Am. Coll. Cardiol. 50:1761–1767; 2007. 31. Rosenzweig, A. Cardiac cell therapy—mixed results from
mixed cells. N. Eng. J. Med. 355:1274–1277; 2006.19. Losordo, D. W.; Renault, M. A. Therapeutic myocardial
angiogenesis. Microvasc. Res. 74:159–171; 2007. 32. Sanberg, P. R.; Park, D. H.; Kuzmin-Nichols, N.; Cruz,
E.; Hossne, Jr., N. A.; Buffolo, E.; Willing, A. E. Mono-20. Losordo, D. W.; Schatz, R. A.; White, C. J.; Udelson,
J. E.; Veereshwarayya, V.; Durgin, M.; Poh, K. K.; cyte transplantation for neural and cardiovascular ische-
mia repair. J. Cell. Mol. Med.; in press.Weinstein, R.; Kearney, M.; Chaudhry, M.; Burg, A.;
Eaton, L.; Heyd, L.; Thorne, T.; Shturman, L.; Hoffmeis- 33. Schuldt, A. J. T.; Rosen, M. R.; Gaudette, G. R.; Cohen,
I. S. Repairing damaged myocardium: Evaluating cellster, P.; Story, K.; Zak, V.; Dowling, D.; Traverse, J. H.;
Olson, R. E.; Flanagan, J.; Sodano, D.; Murayama, T.; used for cardiac regeneration. Curr. Treat. Options Cardio-
vasc. Med. 10:59–72; 2008.Kawamoto, A.; Kusano, K. F.; Wollins, J.; Welt, F.; Shah,
P.; Soukas, P.; Asahara, T.; Henry, T. D. Intramyocardial 34. Silva, S. A.; Sousa, A. L.; Haddad, A. F.; Azevedo, J. C.;
Soares, V. E.; Peixoto, C. M.; Soares, A. J.; Issa, A. F.;transplantation of autologous CD34+ stem cells for intrac-
table angina: A phase I/IIa double-blind, randomized con- Felipe, L. R.; Branco, R. V.; Addad, J. A.; Moreira, R. C.;
Tuche, F. A.; Mesquita, C. T.; Drumond, C. C.; Junior,trolled trial. Circulation 115:3165–3172; 2007.
1310 HOSSNE, JR. ET AL.
A. O.; Rochitte, C. E.; Luz, J. H.; Rabischoffisky, A.; Fibbe, W. E.; Zwaginga, J. J.; Boersma, E.; Schalij, M. J.;
Atsma, D. E. Intramyocardial bone marrow cell injectionNogueira, F. B.; Vieira, R. B.; Junior, H. S.; Borojevic,
R.; Dohmann, H. F. Autologous bone-marrow mononu- for chronic myocardial ischemia. A randomized controlled
trial. JAMA 301:1997–2004; 2009.clear cell transplantation after acute myocardial infarction:
Comparison of two delivery techniques. Cell Transplant. 39. Womble, T. A.; Green, S.; Sanberg, P. R.; Pennypacker,
K. R.; Willing, A. E. CD14+ human umbilical cord blood18(3):343–352; 2009.
35. Tse, H. F.; Kwong, Y. L.; Chan, J. K.; Lo, G.; Ho, C. L.; cells are essential for neurological recovery following
MCAO. Cell Transplant. 17:485–486; 2008.Lau, C. P. Angiogenesis in ischaemic myocardium by in-
tramyocardial autologous bone marrow mononuclear cells 40. Womble, T. A.; Green, S. M.; Nelson, A. P.; Shahaduzza-
man, M. D.; Golden, J. E.; Sanberg, P. R.; Pennypacker,implantation. Lancet 361:47–49; 2003.
36. Tse, H. F.; Siu, C. W.; Zhu, S. G.; Songyan, L.; Zhang, K. R.; Willing, A. E. CD14+ and CD133+ human umbilical
cord blood cells are essential for neurological recoveryQ. Y.; Lai, W. H.; Kwong, Y. L.; Nicholls, J.; Lau, C. P.
Paracrine effects of direct intramyocardial implantation of following MCAO. Cell Transplant. 18:240; 2009.
41. Yerebakan, C.; Kaminski, A.; Liebold, A.; Steinhoff, G.bone marrow derived cells to enhance neovascularization
in chronic ischaemic myocardium. Eur. J. Heart Fail. 9: Safety of intramyocardial stem cell therapy for the ische-
mic myocardium: Results of the Rostock trial after 5-year747–753; 2007.
37. Vanderheyden, M.; Vercauteren, S.; Mansour, S.; Delrue, follow-up. Cell Transplant. 16(9):935–940; 2007.
42. Yerebakan, C.; Sandica, E.; Prietz, S.; Klopsch, C.; Ugur-L.; Vandekerckhove, B.; Heyndrickx, G. R.; Van Haute,
I.; De Bruyne, B.; Timmermans, F.; Wijns, W.; Bartu- lucan, M.; Kaminski, A.; Abdija, S.; Lorenzen, B.; Boltze,
J.; Nitzsche, B.; Egger, D.; Barten, M.; Furlani, D.; Ma,nek, J. Time-dependent effects on coronary remodeling
and epicardial conductance after intracoronary injection of N.; Vollmar, B.; Liebold, A.; Steinhoff, G. Autologous
umbilical cord blood mononuclear cell transplantation pre-enriched hematopoietic bone marrow stem cells in patients
with previous myocardial infarction. Cell Transplant. serves right ventricular function in a novel model of
chronic right ventricular volume overload. Cell Trans-16(9):919–925; 2007.
38. van Ramshorst, J.; Bax, J. J.; Beeres, S. L.; Dibbets- plant. 18(8):855–868; 2009.
Schneider, P.; Roes, S. D.; Stokkel, M. P.; de Roos, A.;
